Findings

What do systematic reviews say?

24 questions · 24 findings · 1 reviews · Haematology

Sort:Best matchNewest Highest certainty Download CSV

No studies found 8 · 33.3%GRADE not reported 0 · 0%Very low 11 · 45.8%Low 4 · 16.7%Moderate 1 · 4.2%High 0 · 0%

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg)

Adverse events: all grades · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19

1 finding from 1 review

Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 98 participants
Very low

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg)

Hospital‐acquired infections ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19

1 finding from 1 review

Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1080 participants
Very low

Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg)

Invasive fungal infection · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19

1 finding from 1 review

Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1080 participants
Very low

Summary of findings table ‐ Methylprednisolone vs dexamethasone

All‐cause mortality up to 30 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19

It is very uncertain whether summary of findings table ‐ Methylprednisolone changes all‐cause mortality up to 30 days compared with dexamethasone (very low certainty).

1 finding from 1 review

Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence 2022 · Cochrane Headline outcomes only
RR 0.51 [0.24, 1.07]
1 study · 86 participants
Very low